Amy Salzhauer
Founder and Managing Partner @ Good Growth Capital
Charleston, United States
Amy Salzhauer is a Founder and Managing Partner at Good Growth Capital, a majority women-owned venture capital fund that is known for its world-leading expertise in technology commercialization, and for finding, funding and growing superior, defensible technology companies that fill pressing societal needs. She was previously the CEO of IgnitionVentures, where she helped start companies worth over US $1 billion out of science labs in areas such as chip-based fuel cells, self-organizing networks, selective brain cooling, and advanced materials.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 45%
Last updated:
For AI agents: llms.txt
Industries Amy Salzhauer invests in
Stages Amy Salzhauer invests in
Countries Amy Salzhauer invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (27%)
- Health Care 2 (18%)
- Medical Device 2 (18%)
- Medical 1 (9%)
- Oncology 1 (9%)
Stage
- Series A 4 (36%)
- Seed 1 (9%)
- Funding Round 1 (9%)
- Convertible Note 1 (9%)
Country
- United States 4 (36%)
- France 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. | Nov 11, 2024 | ||
| AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. | $10.6M / Series A / Nov 11, 2024 | ||
| AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. | Series A / Jan 23, 2023 | ||
| Leuko Labs develops non-invasive white blood cell monitoring device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel,blood draws and laboratory infrastructure. Though its white blood cell monitoring device PointCheck, immunosuppressed patients can now be tested more frequently, moving towards improved quality of life and improved clinical outcomes. | $5M / Series A / Sep 23, 2022 | ||
| Obsidio, Inc. is an early-stage medical device company pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels anywhere in the body regardless of the patient’s coagulopathy. The technology can be used to control bleeding, close off vessels supplying blood to tumor, eliminate abnormal connections betweenarteries and veins, and treat aneurysms. | $1.1M / Convertible Note / Jul 30, 2020 | ||
| Obsidio, Inc. is an early-stage medical device company pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels anywhere in the body regardless of the patient’s coagulopathy. The technology can be used to control bleeding, close off vessels supplying blood to tumor, eliminate abnormal connections betweenarteries and veins, and treat aneurysms. | $116.7K / Convertible Note / May 06, 2020 | ||
| Pryon is an artificial intelligence company focused on enterprise knowledge management. Its natural language processing platform transforms unstructured data into experiences that increase productivity with unmatched accuracy and speed. Pryon’s automated machine learning engines deliver rapid time to value by enriching existing content. Thisno-code approach prevents operational disruption and allows organizations to quickly maximize the business value trapped within their information assets. Pryon was founded by Igor Jablokov, whose previous company defined the state of the art for AI assistants and was acquired by Amazon to form the basis for Alexa. | $20M / Series A / Jun 11, 2019 | ||
| Obsidio, Inc. is an early-stage medical device company pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels anywhere in the body regardless of the patient’s coagulopathy. The technology can be used to control bleeding, close off vessels supplying blood to tumor, eliminate abnormal connections betweenarteries and veins, and treat aneurysms. | $300K / Convertible Note / May 31, 2019 | ||
| Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.The company's therapeutics use proprietary technology that helps the rational design of small molecules that target specific binding pocket regions on RNA, using both sequence and structural specificity, at particularmoments in the RNA splicing process, enabling physicians to target diseases driven by a type of RNA mis-splicing called exon skipping. | $40M / Series A / Jun 15, 2018 | ||
| Obsidio, Inc. is an early-stage medical device company pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels anywhere in the body regardless of the patient’s coagulopathy. The technology can be used to control bleeding, close off vessels supplying blood to tumor, eliminate abnormal connections betweenarteries and veins, and treat aneurysms. | $50K / Convertible Note | ||
| See all 11 investments → | |||
Co-Investors
About Good Growth Capital
Good Growth Capital provides investors with exceptional returns through our ability to source, assess and invest in early-stage transformative science- and technology-based companies in life sciences, data sciences, and greentech/hard sciences.
Good Growth Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Amy Salzhauer
Founder and Managing Partner
|
|||
Carolyne LaSala
Partner and Managing Partner
|
|||
DAVID MENDEZ
Managing Partner
|
|||
DAVID MENDEZ
Managing Partner
|
|||
John Osborne
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Amy Salzhauer invest in?
Amy Salzhauer invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Seed stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Amy Salzhauer?
Public channels for Amy Salzhauer include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Amy Salzhauer last invest?
The most recent investment recorded for Amy Salzhauer closed in Nov 2024. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
